Head And Neck Cancer NM Flashcards
Lip and oral cavity cancer most common type
Tobacco and alco - - SCC 95%
Lip and oral cavity cancer
Most common location
Tongue (oral tongue more likely LN)
FOM (more likely LN)
Gingiva
Lip and oral cavity cancer
Premalignant
Leukoplakia
Erythroplakia
Lip and oral cavity cancer T1
Lip and oral cavity cancer T2
Lip and oral cavity cancer T3
Lip and oral cavity cancer T4a
Lip and oral cavity cancer T4b
Lip and oral cavity cancer N
Lip and oral cavity cancer M
Lung
Bone
Liver
Ca of lip LN
IA
IB
CA of alveolar ridge or hard palate LN
Low potential for MTS
IB
II-IV
retropharyngeal - less common
Level VII = ant sup mediastinal still regional
Lip and oral cavity cancer CT limit
Small lesions
Mucosal surface
Dental amalgam streak artifact
Lip and oral cavity cancer PET/CT
Unknown primary
False positive: muscle, brown fat, lymphoid tissue, mucosa
Oropharynx p16- risk
Tobacco
Alco
Men
Elderly
Oropharynx p16- subsites
Base of tongue (lingual tonsil)
Palatine tonsils
Pharyngeal walls
Soft palate and uvula
Hypopharynx T3
Hemilarynx fixation
Oropharynx cancer M
Lung
Bone
Liver
Oropharynx p16- most important prognostic factor
Regional LN
Palatine tonsils and base of tongue - - II, III, retropharyngeal
Posterior pharyngeal wall - - retropharyngeal
Base of tongue - - bilateral
Also I, IV and V
Oropharynx p16 important
Keratizing
Mucosal ulceration
Resistant
Poor response
Worse prognosis
Higher rate of M
Locoregional recurrence
Oropharynx p16- T1
Oropharynx p16- T2
Oropharynx p16- T3
Oropharynx p16- T4a
Oropharynx p16- T4b
Oropharynx p16+ most common location
Base of tongue (lingual tonsil)
Palatine tonsil
Oropharynx p16+ risk
Younger men
No tobacco or alco
High status
Increased number of partners
HPV type 16
Also types 18, 31, 33
Oropharynx p16+ N
Oropharynx p16+ regional LN
More significant than p16-
II and III
Oropharynx p16+ important
Non keratizing
Cystic nodes - - negative on PET
Better prognosis, respond
More M1, atypical sites
Adult with new cystic lymphadenopathy in upper neck
Oropharynx p16+
Oropharynx p16+ T1
Oropharynx p16+ T2
Oropharynx p16+ T4a
Oropharynx p16+ T4b
Oropharynx p16+ T3
Hypopharynx
95% SCC
Hypopharynx subsites
Sinus pyriformis - - encase ICA - - >270°
Hypopharyngeal wall (lateral and posterior)
Postcricoid region - - Plammer-Vinson sy, Paterson-Kelly sy
Hypopharynx M
Lung
Bone
Liver
Hypopharynx regional LN
Early dissemination
75% at presentation
20-40% contralateral Nodal MTS at diagnosis
II-IV
Retropharyngeal
VI
Medistianal nodes (VII) are still regional
40% of clinically N0 - - pathologically N+
Hypopharynx PET
Staging
Prior to endoscopy
Hypopharynx important
60% keratizing
“hot potato” voice
Poor survival
Worst prognosis of all head and neck SCC
Hypopharynx risk
Men
Tobacco
Alco
Fe def
Vit C def
Hypopharynx T1
Hypopharynx T2
Hypopharynx T3
Hypopharynx T4a
Hypopharynx T4b
Hypopharynx T4b
Hypopharynx T4b
Oropharynx p16+
Nasopharynx keratizing SCC
Smoke, HPV
Locally advanced at presentation
Nasopharynx non keratizing SCC
Differentiated type
Undifferentiated type - most common 90%
EBV
Better prognosis
Nasopharynx basaloid SCC
Men, 30-40, 50-60
China endemic
Nasopharynx T
Nasopharynx N
Nasopharynx M
Bone
Lung
Liver
Rare
High potential
Poor prognosis
Highest rate of LN MTS among all SCC of head and neck
Nasopharynx
Nasopharynx regional LN
80-90% at presentation
Retropharyngeal 70%
II 70%
Spinal accessory chain V
Well controlled by radiation unlike other SCC
Nasopharynx CT
Mass in lateral pharyngeal recess of nasopharynx with deep extension and cervical adenopathy
Most frequent - lateral wall = fossa of Rosenmueller
Nasopharynx PET
Strong avidity
Submucosal tumor
Perineural spread - - mandibular nerve
Superior in restating and evaluating treatment effectiveness
Nasopharynx T0
Malignant cervical lymphadenopathy +EBV
Nasopharynx presentation
Unilateral hearing loss
Painless upper cervical lymphadenopathy
Nasopharynx stage I-II treatment
Radio
Cures 60-90%
Nasopharynx most powerful prognostic factor
Stage at presentation
Nasopharynx T1
Nasopharynx T2
Nasopharynx T3
Nasopharynx T4
Nasopharynx
Maxillary sinus cancer
Most common
Tumor arise from mucosa - - nodule or mass
Small tumor - - nasal congestion
From inverted papilloma - - HPV - - good prognosis
Maxillary sinus T
Maxillary sinus, nasal cavity and ethmoid sinus M
Bone
Lung
Liver
Low incidence
Maxillary sinus, nasal cavity and ethmoid sinus regional LN
Low incidence
Usually unilateral IB, II, retropharyngeal
Maxillary sinus, nasal cavity and ethmoid sinus PET
SUV correlate with tumor grade
Strong avidity in metastatic LN
Maxillary sinus, nasal cavity and ethmoid sinus risk, important
Occupational exposure
Tobacco, alco
HPV, EBV
Men, > 45y
Keratizing SCC 80% - - worse prognosis
Adenocarcinoma - - better prognosis
Olfactory neuroblastoma
ENB - - unilateral nasal obstruction
Female “<20,>50
Nasal cavity and ethmoid sinus T
ENB CT
Superior part of tumor in intracranial fossa
Inferior part in upper nasal cavity
Maxillary sinus T1
Maxillary sinus T2
Maxillary sinus T3
Maxillary sinus T4a
Maxillary sinus T4b
Nasal cavity T1
Nasal cavity T2
Nasal cavity T3
Nasal cavity T4a
Nasal cavity T4b
Supraglottis
Epiglottis - - poorly resistant to tumor penetration
SCC 95%
Non keratizing
Few early symptoms unlike others
Supraglottis T1-3
Supraglottis regional LN
Lymphatic rich
Early spread to II-IV
Bilateral, contralateral
Glottis
Most common in larynx
Keratizing
True cords - - hoarseness
Irregular thickening of mucosa - - ulcer
Glottis T1-2
Glottis regional LN
No lymph in vocal cords - - rare
Subglottis
Ulcerative mucosa - - large exophytic or fungating mass
50% cartilage involvement
Subglottis T1-2
Glottis and subglottis T3
Larynx T4a-b
Larynx M
Lung
Liver
Diaphragm
Larynx PET
Complete staging of advanced laryngeal cancer
Strong avidity in metastatic LN
False positive: laryngeal muscle activation with contralateral vocal cord paralysis
Most useful in postlaryngectomy
Supraglottis T1
Supraglottis T2
Supraglottis T3
Supraglottis T4a
Glottis T1
Glottis T2
Glottis T3
Glottis T4a
Subglottis T1
Subglottis T2
Subglottis T3
Subglottis T4a
Larynx T4b
Larynx T4b
Major salivary gland
Uncommon
Parotid - - most common 95%
Mucoepidermoid (MECa) - - low grade, rare LN, superficial parotid lobe, 1-4 cm at presentation
Adenoid cystic carcinoma (ACC) - - highest incidence of distant MTS, parotid gland, 1-3 cm at presentation,
MECa>ACC
Submandibular
ACC>MECa>adenocarcinoma
Sublingual
Warthin tumor
Benign
Female
Smoker
Tc pert avid
Major salivary gland T
Major salivary gland M
Lung
Brain
Bone
Hem > lymph
Lung > lymph
MECa M
Mandible
Skull base
ACC M
Highest incidence of distant MTS
Highest spread via perineural pathway of all head and neck tumors
Predictor of distant MTS
Salivary gland
Tumor >3cm
Solid
Local recurrence
N1
Major salivary gland regional LN
Ipsilateral
Jugulodigastric level III
Major salivary gland PET
False positive 30% - - Warthin tumor
Pleomorphic adenoma - moderste/intense uptake - - hard to dd benign vs malignant
High grade salivary tumor SUV>5.0
ACC– slow growth - - low SUV, non avid metastatic LN
MECa - - no Tc pert uptake vs Warthin tumor
Major salivary gland presentation
Palpable painless mass
Facial nerve dysfunction - - negative prognostic factor
Parotid - - most positive prognostic factor
20 years after radiation in low dose
Parotid neoplasm
Major salivary gland treatment
Surgery (first choice
Complication - - facial nerve damage
Chemo
Radio for non resectable (stage IVB/IVC)
Major salivary gland T1
Major salivary gland T2
Major salivary gland T3
Major salivary gland T3
Major salivary gland T4a
Major salivary gland T4a
Major salivary gland T4a
Major salivary gland T4a
Major salivary gland T4b
Major salivary gland T4b
Epiglottis carcinoma
Residual disease on PET
Focal and asymmetric uptake with intensity greater than surrounding normal tissue and blood vessels
Post radiation inflammation on PET
Diffuse uptake within radiation field
After chemo PET
At least 10 days
Within 6 months and 1 year after initial PET
After radio PET
2-3 months
Cancer of larynx
Encased artery
> 270° surrounded
Primary tonsil cancer
Tonsil Cancer
Level II LN
Retropharyngeal nodes level VIIa
Subglottis regional LN
Paratracheal
Sup mediastinal
CT best for
Lower part of neck
Osseous involvement
Left tonsil
Submental and Submandibular nodes
IA and IB - - lip cancer
IB - - ca of alveolar ridge or hard palate, maxillary sinus (rare)
Upper jugular
Level II
Ca of alveolar ridge or hard palate
Oropharynx
Hypopharynx
Nasopharynx
Maxillary sinus (rare)
Supraglottis
Mid jugular
Level III
Oral cavity
oropharynx
Hypopharynx
Supraglottis
Salivary gland
Lower jugular and medial supraclavicular
Level IV
Oral cavity
Hypopharynx
Supraglottis
N0 + positive PET
Neck dissection, not SLNB
Full negative work up
FDG reveal primary
20-40%
History of lymphoma post treatment
Physiologic uptake in Waldeyers ring
Hodgkins lymphoma after chemo
Thymic hyperplasia
Buccal cancer after left neck dissection
Physiologic uptake in right tonsil
Larynx cancer after surgery and chemo radio
Inflammation around tracheostomy
Treated breast cancer
Reactive LN
Tonsil
Elderly with lung cancer
Pleomorphic adenoma or Warthin tumor
Retropharyngeal
Alveolar ridge and hard palate
Oropharynx p16-
Hypopharynx
Nasopharynx
Maxillary sinus and nasal cavity
Cervical cancer of unknown origin
Neck dissection
Tonsillectomy
Radio of all mucosal sites and both sides of neck
Detection of primary tumor improve survival
FDG sensitivity 69%